A feature in Bloomberg today highlights GSK's unusual decision to give its research division in China the lead role in neuroscience drug development.
GlaxoSmithKline wasn't the only Big Pharma company to set up R&D operations in China. But a feature in Bloomberg today highlights GSK's unusual decision to give its China research division the lead in its neuroscience drug development effort.
The pharma giant intends to back 5 to 7 drug and device startups in the bioelectronics field over the next 5 years in the latest example of GSK's commitment to come up with a blend of specially focused venture funds aimed at seeding new companies that dovetail with their R&D specialties.
California startup SetPoint Medical has hauled in $27 million in venture funding to support its neuromodulation device to treat inflammatory diseases, attracting heavyweights like GlaxoSmithKline, Covidien and Boston Scientific.
As the company's current scandal in China shows, Witty was caught somewhat flat-footed by problems there, and some investors wonder whether Witty's reforms have been rigorous enough.
GSK will begin adding 2-D barcodes to its Fluarix Quadrivalent 4-in-1 influenza vaccine, which the FDA cleared for shipping on Monday. Over the next 6 months GSK will add the barcode technology to the packaging of more vaccines.
The FDA asked for a few more months to review GSK's app on albiglutide, which would compete with Novo Nordisk's Victoza and Bristol-Myers Squibb and AstraZeneca's Byetta and Bydureon, among others.
Glaxo says that the FDA asked for more time to review the information the big pharma company had submitted in response to the agency's queries and pushed back the deadline to April 15, 2014.
Big Pharma companies are fighting to stay out of the spotlight as authorities show up to visit them.
India's Intellectual Property Appellate Board (IPAB) has pulled the patent that GlaxoSmithKline had for its breast cancer drug Tykerb, a salt form of lapatinib, while upholding the patent on the original API.